Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated ma...

por van Keep, Marjolijn, Gairy, Kerry, Seshagiri, Divyagiri, Thilakarathne, Pushpike, Lee, Dawn
Publicado 2016

Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model

por Schurer, Marieke, Patel, Renu, van Keep, Marjolijn, Horgan, Jake, Matthijsse, Suzette, Madin-Warburton, Matthew
Publicado 2023

Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective

por Dunlop, Will, van Keep, Marjolijn, Elroy, Peter, Perez, Ignacio Diaz, Ouwens, Mario J. N. M., Sarbajna, Tina, Zhang, Yiduo, Greystoke, Alastair
Publicado 2021

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

por Emery, Paul, Van Keep, Marjolijn, Beard, Steve, Graham, Chris, Miles, LaStella, Jugl, Steffen Marc, Gunda, Praveen, Halliday, Anna, Marzo-Ortega, Helena
Publicado 2018

Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?

por Urbanus, Anouk T., van Keep, Marjolijn, Matser, Amy A., Rozenbaum, Mark H., Weegink, Christine J., van den Hoek, Anneke, Prins, Maria, Postma, Maarten J.
Publicado 2013